0000-00-00 |
|
|
|
External link to document |
2021-11-16 |
1 |
Complaint |
U.S. Patent No. 10,039,718 (the “’718
patent”) and U.S. Patent No. 10,786,518 (the “’518 patent”) (together…Orange Book Patents-
In-Suit”), and U.S. Patent No. 8,497,396 (the “’396 patent”) and U.S. Patent No. 9,428,473…“’473 patent”) (together, the “Process Patents-In-Suit”) (all patents collectively, the “Patents-In-
…the expiration of the ’718 patent, ’518 patent, ’396 patent
and ’473 patent (including such actions by… infringement of the
’718 patent, ’518 patent, ’396 patent and ’473 patent under 35 U.S.C. §§ 271 (a) |
External link to document |
2023-07-07 |
141 |
Notice of Service |
Invalidity Contentions Regarding U.S. Patent No. 10,039,718 (the 718 Patent) filed by Lupin Limited, Lupin Pharmaceuticals…16 November 2021
1:21-cv-01621
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2023-08-10 |
149 |
Notice of Service |
Daniel R. Kuritzkes, M.D. Regarding U.S. Patent No. 10,039,718, (5) Opening Expert Report of Leah Appel…Appel, Ph.D., Regarding Validity of U.S. Patent No. 10,039,718 filed by Gilead Sciences Ireland UC, Gilead… Kuritzkes, M.D. Regarding Infringement of U.S. Patent No. 10,786,518 and Objective Indicia of Non-obviousness…Regarding Objective Indicia of Nonobviousness of U.S. Patent No. 10,786,518, (3) Expert Report of Gregory K.…16 November 2021
1:21-cv-01621
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2023-08-10 |
150 |
Notice of Service |
.D., Sc. Regarding the Validity of U.S. Patent No. 10,039,718 filed by Lupin Limited, Lupin Pharmaceuticals…Lynne Thio, M.D. Regarding the Validity of U.S. Patent No. 10,786,518, the [CONFIDENTIAL] Expert Report…. Regarding the Enablement of Prior Art to U.S. Patent No. 10,786,518, and the [CONFIDENTIAL] Expert report…16 November 2021
1:21-cv-01621
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2023-10-19 |
180 |
Notice of Service |
Expert Report of Leah Appel, Ph.D., Regarding U.S. 10,039,718; (2) Rebuttal Expert Report of Dr. Daniel R. …. Kuritzkes, M.D. Regarding Validity of U.S. Patent No. 10,786,518; and (3) Rebuttal Expert Report of …Williams III, Ph.D., Regarding the Validity of U.S. Patent No. 10,786,518 filed by Gilead Sciences Ireland…16 November 2021
1:21-cv-01621
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |